Fireside Chat: Aligning Regulatory & Funding Strategies to Accelerate Myeloid Drug Translation

Time: 4:15 pm
day: Conference Day One

Details:

• What endpoints, comparators, and biomarkers regulators are prioritizing after a wave of failures in CD47, ILT, and TREM2-based programs
• How to structure early-phase trials and IND packages to manage risk, especially for novel myeloid reprogramming or depletion strategies
• What funders (VCs, pharma partners, government) need to see in terms of differentiation, scalability, and patient stratification to greenlight programs

Speakers:

Juho Jalkanen Dr. Juho Jalkanen is an experienced biopharmaceutical industry executive with extensive leadership experience across key functional areas including operations, business development, clinical development, medical and Read more

Martin Treder Dr. Martin Treder is a seasoned biopharmaceutical leader with two decades of experience in oncology-focused drug discovery and early development. As CSO at LTZ Therapeutics, Read more